Drug intelligence / Profile preview

SENT006

Development stage: Preclinical
Lead developer: Sentio BioSciences

Overview

SENT006 is an investigational oncology therapeutic currently in the preclinical stage of development. Developed by Sentio BioSciences, the asset is part of a pipeline focused on novel cancer treatments. While the specific mechanism of action, molecular target, and modality remain undisclosed by the sponsor as of 2024, SENT006 is being evaluated for its potential application in treating various malignant conditions.

Beyond the preview

Go deeper on SENT006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENT006.

Explore the full profile